Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

1(17%)

Results Posted

40%(2 trials)

Phase Distribution

Ph phase_2

17%

Ph phase_3

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(5)

Detailed Status

Completed5

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (20.0%)

Phase 34 (80.0%)

Trials by Status

recruiting117%

completed583%

Recent Activity

1 active trials

Showing 5 of 6

completedphase_3

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

NCT05463068

completedphase_3

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)

NCT05112848

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT05463068Phase 3

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Completed

NCT05875701Phase 3

Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

Completed

NCT05372588Phase 3

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines

Completed

NCT05249816Phase 3

Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine

Completed

NCT05112848Phase 2

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)

Completed

NCT04834869

COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6